Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Universal Boost COVID-19 T-Cell Vaccine
- Development stage
- Unknown
- Lead developer
- ImmunityBio
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Sublingual, Oral, Intranasal
01
Overview
A dual-antigen COVID-19 vaccine developed as a universal booster, designed to be administered to individuals already vaccinated with a spike-only antibody-based COVID-19 vaccine. This candidate vaccine utilizes a human adenovirus serotype 5 (hAd5) platform encoding both the SARS-CoV-2 spike (S) and nucleocapsid (N) proteins[2][3]. The aim is to drive both T cell and antibody immunity, providing broad, variant-independent protection. Phase 1 studies have demonstrated potent T cell responses, including enhanced immunity against viral variants, with no serious adverse events observed[2][3]. The vaccine is intended for use as a booster, particularly targeting breakthrough infections, and is being evaluated through multiple administration routes: subcutaneous, sublingual, oral, and intranasal[2][3].
- Brand names
- Universal Boost COVID-19 T-Cell Vaccine
- Other names
- ImmunityBio SISONKE Boost TrialhAd5 S+N COVID-19 Vaccine
02
Targets
SARS-CoV-2 spikeN (Nucleocapsid protein)
Beyond the preview
Go deeper on Universal Boost COVID-19 T-Cell Vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Universal Boost COVID-19 T-Cell Vaccine.